Skin Elements Limited (SKN) AI Stock Analysis

• Market Cap: AU$3.15M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 12.92%
• EPS Growth: 18.42%
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 1,075,214,100
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Skin Elements Limited exhibits significant financial instability, characterized by declining revenue, negative equity, and liquidity challenges. The absence of technical analysis data and a negative P/E ratio further emphasize the company's precarious position. Investors should be cautious due to the high-risk profile and lack of positive financial or market indicators.

Skin Elements Limited Business Overview & Revenue Model

Company Description

Skin Elements Limited (SKN) is an Australian-based company specializing in the development and commercialization of natural skincare products. The company focuses on creating innovative, eco-friendly products that cater to the health and wellness sector. Their core products include organic skincare lines, sun protection solutions, and natural sanitizing products, all formulated with plant-based ingredients to ensure safe and effective skincare solutions.

How the Company Makes Money

Skin Elements Limited generates revenue primarily through the sale of its natural skincare and sanitizing products. The company's revenue streams include direct sales via online platforms, partnerships with retail distributors, and wholesale agreements with health and beauty stores. Strategic collaborations with various distribution channels and an emphasis on expanding their market presence both domestically and internationally contribute to their earnings. In addition, Skin Elements leverages its research and development capabilities to create proprietary formulas, which can also lead to licensing opportunities, enhancing its revenue potential.

Skin Elements Limited Financial Statement Overview

Summary

Skin Elements Limited is facing significant financial challenges. The income statement highlights ongoing operational losses and declining revenue. The balance sheet reveals a concerning negative equity position and high liabilities, raising solvency concerns. Cash flow analysis further emphasizes liquidity struggles, with persistent negative free cash flow indicating a need for improved cash management and operational efficiency.

Income Statement

Skin Elements Limited has experienced a decline in total revenue over recent years, with the most recent annual report showing a revenue of 416,202 down from 1,408,330 in 2022. Despite a positive gross profit margin in the latest period, net income remains negative, indicating ongoing operational losses. Both EBIT and EBITDA margins are significantly negative, showing substantial operational inefficiencies.

Balance Sheet

The company has a negative stockholders' equity of -1,632,838, reflecting a weak financial position. The debt-to-equity ratio is not calculable due to negative equity, but total liabilities exceed assets, leading to negative equity. This suggests significant solvency issues. The equity ratio is likewise negative, indicating a potential risk of financial instability.

Cash Flow

Operating cash flow remains negative, though slightly improved from previous years. Free cash flow is also negative, pointing to liquidity challenges. The operating cash flow to net income ratio indicates inefficiencies in converting revenue to cash, as the company continues to generate insufficient cash to cover its operational expenses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	416.20K	194.13K	1.41M	288.74K	425.17K
Gross Profit	361.87K	-204.55K	742.98K	-213.47K	-182.40K
EBITDA	-2.08M	-12.08M	-1.17M	-2.65M	-2.24M
Net Income	-2.16M	-11.42M	-1.58M	-3.04M	-1.91M
Balance Sheet
Total Assets	1.44M	1.69M	11.10M	11.03M	10.22M
Cash, Cash Equivalents and Short-Term Investments	115.07K	358.43K	748.05K	287.63K	205.95K
Total Debt	731.73K	17.75K	24.53K	30.99K	500.00K
Total Liabilities	3.08M	1.08M	1.05M	1.42M	1.01M
Stockholders Equity	-1.63M	604.80K	10.05M	9.60M	9.21M
Cash Flow
Free Cash Flow	-279.38K	-1.84M	-1.50M	-2.74M	-1.93M
Operating Cash Flow	-279.38K	-1.84M	-1.50M	-2.70M	-1.90M
Investing Cash Flow	0.00	0.00	0.00	-36.41K	-30.00K
Financing Cash Flow	36.02K	1.45M	2.69M	2.82M	2.02M

Skin Elements Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOT	53 Neutral	AU$304.01M	-3.31	―	―	456.50%	-457.14%
EWC	37 Underperform	AU$178.58M	-0.27	―	―	-67.88%	-19190.91%
SKN	30 Underperform	AU$3.15M	―	―	―	12.92%	18.42%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

Skin Elements Limited Corporate Events

Skin Elements Advances ECO-Nurture and SuprCuvr to Commercialization Phase

Skin Elements Limited reported a productive quarter with significant advancements in their core product lines, ECO-Nurture and SuprCuvr. ECO-Nurture, a sustainable plant bio-stimulant, is nearing the end of successful trials in New Zealand’s kiwifruit orchards, with plans for commercial rollout in the second half of 2025. SuprCuvr, a plant-based hospital-grade disinfectant, is being tested in Melbourne’s public transport and agriculture sectors, presenting a substantial market opportunity. The company also completed an oversubscribed rights issue, raising $656k, supporting their commercialization efforts.

Skin Elements Completes Share Allotment to Bolster Capital Structure

Skin Elements Limited has completed an allotment of 43,333,333 fully paid ordinary shares as part of oversubscriptions received under its Entitlement Issue Prospectus. This move, announced and allotted on March 13, 2025, signifies the company’s compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards. The successful allotment reflects the company’s strategic efforts to enhance its capital structure, potentially strengthening its market position and offering stakeholders confidence in its operational and financial governance.

Skin Elements Limited Issues New Unquoted Securities

Skin Elements Limited announced the issuance of 43,333,333 unquoted securities, specifically options expiring on February 21, 2028, with an exercise price of $0.01. This move is part of the company’s strategic financial activities, potentially impacting its capital structure and providing opportunities for stakeholders to engage with the company’s growth prospects.

Skin Elements Limited Announces Quotation of New Securities on ASX

Skin Elements Limited announced the application for the quotation of 43,333,333 ordinary fully paid securities on the ASX, following additional oversubscriptions from a non-renounceable rights entitlement issue prospectus dated December 19, 2024. This move is expected to enhance the company’s capital base, potentially strengthening its market position and providing more resources for growth and expansion in the skincare industry.

Skin Elements Limited Announces Successful Oversubscription in Share Issue

Skin Elements Limited announced that it has received additional oversubscription applications for 43,333,333 new shares and options, raising an extra $130,000 before costs. This development follows the results of their entitlement issue and highlights the growing investor interest in the company’s offerings, potentially strengthening its market position and financial standing.

Skin Elements Completes Share Allotment Amid Strong Investor Interest

Skin Elements Limited has completed an allotment of 4,497,470 fully paid ordinary shares, which were oversubscriptions from its Entitlement Issue Prospectus dated December 2024. This move signifies the company’s compliance with relevant provisions of the Corporations Act and indicates a robust interest in its shares, potentially strengthening its market position and stakeholder confidence.

Skin Elements Limited Issues New Unquoted Securities

Skin Elements Limited has announced the issuance of 4,497,470 unquoted securities, specifically options expiring on February 21, 2028, at an exercise price of $0.01. This move is part of the company’s strategic financial activities, potentially impacting its capital structure and providing opportunities for future growth and investment, which could influence its market positioning and stakeholder interests.

Skin Elements Limited Announces Quotation of Oversubscribed Securities

Skin Elements Limited announced the quotation of 4,497,470 ordinary fully paid securities on the ASX, following oversubscriptions from its non-renounceable rights issue prospectus dated December 19, 2024. This move reflects strong investor interest and is likely to enhance the company’s capital base, potentially strengthening its market position and providing additional resources for growth initiatives.

Skin Elements Limited Releases Interim Financial Report for December 2024

Skin Elements Limited has released its interim financial report for the period ending December 31, 2024. This report provides insights into the company’s financial performance and strategic direction, which may influence its market positioning and stakeholder interests. The release of this report is crucial for investors and stakeholders as it outlines the company’s financial health and future prospects.

Skin Elements Extends Securities Offering Deadline

Skin Elements Limited announced an extension of its securities offering closing date to February 28, 2024, with trading on a deferred settlement basis beginning on March 3, 2025. This update aims to provide more time for potential investors and could impact the company’s capital raising efforts, potentially affecting its market positioning and stakeholder interests.

Skin Elements Extends Closing Date for Securities Issue

Skin Elements Limited announced an update regarding its proposed issue of securities, extending the closing date to February 28, 2024. This extension allows the company more time to finalize the issuance process, potentially impacting its capital structure and investor relations by aligning with market expectations for transparency and regulatory compliance.

Skin Elements Extends Entitlement Issue Closing Date

Skin Elements Limited announced an extension of its non-renounceable entitlement issue closing date to 28 February 2025, allowing shareholders more time to consider participation. This extension reflects the company’s focus on shareholder engagement and could potentially impact its market operations and shareholder value positively.